title: Therapeutic effect of sunitinib on diabetes mellitus related ovarian injury: an experimental rat model study.
abstract: The aim of our study is to investigate the effect of sunitinib on diabetes mellitus related-ovarian injury and fibrosis in rat models. An experimental diabetes mellitus model was created in 16 rats, and eight rats with normal blood glucose levels were included in control group (Group-1). The diabetic rats were divided into two groups:diabetic control group (water given) - Group-2 and sunitinib treatment group - Group-3. After four weeks, bilateral oophorectomy was performed and ovaries were examined histologically. The groups were compared by Student's t-test, analysis of variance (ANOVA) and Mann-Whitney's U-test. There was a significant increase in no-medication (water given) diabetic rat's ovary (Group-2) in terms of follicular degeneration, stromal degeneration, stromal fibrosis and NF-kappaB immune-expression compared with control group normal rats' ovary (Group-1) (p < 0.0001). Stromal degeneration (p = 0.04), stromal fibrosis (p = 0.01), follicular degeneration (p = 0.02), NF-kappaB immune-expression (p = 0.001) significantly decreased in sunitinib-treated diabetic rat's ovary (Group-3) when compared with no-medication (water given) diabetic rat's ovary (Group-2) (p < 0.05). When we used sunitinib in the treatment of diabetic rats, ovarian injury, fibrosis and NF-kappaB immunoexpression decreased significantly. The effects of sunitinib in rat models give hope to the improved treatment of premature ovarian failure due to diabetes mellitus in humans.
authors.affiliation: Physiology Department, Istanbul Bilim University School of Medicine , Istanbul , Turkey .
authors.forename: Oytun
authors.initials: O
authors.lastname: Erbas
authors.forename: Halil Gursoy
authors.initials: HG
authors.lastname: Pala
authors.forename: Emel Ebru
authors.initials: EE
authors.lastname: Pala
authors.forename: Burcu
authors.initials: B
authors.lastname: Artunc Ulkumen
authors.forename: Levent
authors.initials: L
authors.lastname: Akman
authors.forename: Tulay
authors.initials: T
authors.lastname: Akman
authors.forename: Fatih
authors.initials: F
authors.lastname: Oltulu
authors.forename: Huseyin
authors.initials: H
authors.lastname: Aktug
authors.forename: Altug
authors.initials: A
authors.lastname: Yavasoglu
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D005355:Fibrosis; D007150:Immunohistochemistry; D007211:Indoles / Q000494:pharmacology*; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D016649:Primary Ovarian Insufficiency / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D011758:Pyrroles / Q000494:pharmacology*; D051381:Rats; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D016328:NF-kappa B; D011758:Pyrroles; D000077210:Sunitinib
keywords: Advanced glication end products; NF-kappaB; diabetes mellitus; premature ovarian failure; receptor of advanced glication end products; sunitinib